Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2a study of TAC-201 in Japanese cedar pollinosis using an environmental exposure chamber
jRCT2080220794Phase 2
- Sponsor
- Taiho Pharmaceutical Co., Ltd.
- Start
- Jul 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, randomised trial in Japanese cedar pollinosis and seasonal allergic rhinitis (SAR) comparing TAC-201 arm with Placebo arm (2 arms).
02
Drugs
TAC-201
03
Conditions
Japanese cedar pollinosisseasonal allergic rhinitis (SAR)
Beyond the preview
Go deeper on jRCT2080220794.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080220794.